

Evaluation of nine children with reversible posterior encephalopathy syndrome

Faruk Incecik, M. Ozlem Hergüner, Sakir Altunbasak, Fatih Erbey¹, Goksel Leblebisatan²

Departments of Pediatric Neurology, ¹Pediatric Oncology, and ²Pediatric Hematology, Cukurova University Medical Faculty, Adana, Turkey

Abstract

Background: Reversible posterior leukoencephalopathy syndrome (PRES) is a neurological disorder characterized by signs of posterior cerebral edema upon radiographic examination. **Materials and Methods:** We retrospectively analyzed the records of nine children with the diagnosis of PRES. **Results:** Of the nine patients, seven were receiving immunosuppressive therapy and two were acute hypertensive crisis associated with renal disease. Immunosuppressive drugs were intrathecal methotrexate in two patients, cyclosporine in two patients, intrathecal cytarabine in one patient, cyclophosphamide in one patient, and intravenous immunoglobulin (IVIg) in another one patient. The most presenting symptoms were seizure, headache, and altered consciousness. Six patients had seizures. Altered consciousness was present in four patients. Headache and nausea or vomiting was present also in six patients. Visual abnormalities were noted in two patients. Magnetic resonance imaging (MRI) studies showed white-matter abnormalities suggestive of edema in the posterior regions of the cerebral hemispheres, but the changes often involved other cerebral areas, the brain stem, basal ganglia or the cerebellum. The patients were treated with antihypertensive medications, and immunosuppressive therapy was withdrawn. In all the patients, the clinical and radiological findings resolved morly completely. **Conclusion:** Reversible posterior leukoencephalopathy may develop in patients who have renal insufficiency or hypertension or who are immunosuppressed. This syndrome should be recognized immediately and trigger agents can be discontinued to prevent long-term sequelae.

Key words: Children, clinical and radiological findings, reversible posterior leukoencephalopathy syndrome

Address for correspondence:

Dr. Faruk Incecik,
Toros mah, 40 Sok,
Omer Bayram Havus Apt.,
Kat: 11, No: 11, Adana, Turkey.
E-mail: fincecik@yahoo.com

DOI: 10.4103/0028-3886.55605

Introduction

Reversible posterior leukoencephalopathy syndrome (PRES) is a clinical and radiological syndrome, first described by Hinchey *et al.* in 1996.^[1] The main causes of this condition include hypertensive crisis, renal failure, fluid retention, and some immunosuppressive drugs. But, it has recently been identified in a wide variety of conditions, including posttransplantation stage of liver diseases, acute chest syndrome in sickle cell disease, hemolyticuremic syndrome, acute intermittent porphyria, malignancies, vasculitis,

eclampsia, transfusion, and erythropoietin, oxybutynin or intravenous immunoglobulin (IVIg) treatment.^[2-5]

The most common clinical manifestations of PRES are seizures, headache, nausea and vomiting, altered mental status, decreased alertness, cortical blindness, and transient motor deficits. The main finding in neuroimaging is posterior white matter oedema, which is predominating in the occipital and parietal lobes and posterior fossa structures.^[1]

In this study, we evaluated clinical and radiological findings in nine children who were diagnosed with PRES.

Materials and Methods

We retrospectively analyzed the records of nine children with the diagnosis of PRES between January 2006 and June 2008 at the University of Cukurova Hospital, Turkey.

Diagnostic criteria for PRES included an increased diffusion coefficient in regions of T2 hyperdensities on diffusion-weighted imaging (DWI) with associated symptoms of neurological alterations such as headache, loss of consciousness or seizures. Data were collected on their age at presentation, gender, symptoms, physical and neurological examination findings, radiological findings, and primary underlying etiology.

All of the magnetic resonance imaging (MRI) and electroencephalography (EEG) studies were also completed within the first 24-48 h of presentation. MRI was performed with a 1.5-T scanner and precontrast imaging sequences [T1-weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR)] and postcontrast T1-weighted images were also obtained. Arterial blood pressure was monitored in all patients and serum biochemistry panel was obtained.

Results

We identified nine patients (seven boys and two girls), who had the characteristic clinical and imaging features of PRES. The mean age of the children was 7.78 ± 3.76 years (range 3-13 years). The primary etiology, in two patients was taking intrathecal methotrexate for acute lymphoblastic leukaemia (ALL-L2), in another two patients was taking cyclosporine for allogeneic bone marrow transplantation for thalassemia, in one patient was taking intrathecal cytarabine (Ara-C) for acute myeloblastic leukemia (AML), in one patient was taking cyclophosphamide for nonHodgkin's lymphoma, in one patient was taking IVIg for Guillain Barre syndrome (GBS), and the last two patients had chronic renal failure and acute hypertensive crisis.

The most presenting symptoms were seizure, headache and altered consciousness. Six patients had seizures. Four of these had generalized tonic-clonic seizures (GTC), and two had focal seizures. Altered consciousness was present in only four patients. Headache and nausea or vomiting was present in six patients. Visual abnormalities were noted in two patients, consisted of blurred vision.

These signs and symptoms resolved after discontinuing of immunosuppressive drugs and IVIg in seven cases, and after starting antihypertensive management in two

cases. The median time to clinical resolution was four days (range, 2-12 days).

The most common location of the white-matter abnormalities on MRI was in the posterior regions of the cerebral hemispheres [Figure 1a and b; patient 1]. Isolated parietal and occipital involvement was noted in six patients. We showed involvement of frontal lobe in two patients, temporal lobe in one patient, cerebellar in one patient, and basal ganglia in one patient on MRI [Figure 2; patient 2]. These abnormalities were bilaterally symmetric in five cases and asymmetric in the other five patients. In follow-up, one month later, neuroimaging changes had disappeared or almost completely resolved in all of the patients [Figure 3a and b; patient 1].

EEGs were obtained for only seven of them; diffuse slowing activity was observed in two patients and normal in five patients. Clinical and neuroimaging findings are summarized in Table 1.

Discussion

The most common clinical manifestations of PRES are headache, nausea and vomiting, altered mental status, decreased alertness, seizures, cortical blindness, and transient motor deficits. In the patients with PRES, seizures are common at the onset of neurologic symptoms but can also develop later. The seizures are usually GTC type and multiple. Temporary restlessness and agitation may alternate with lethargy. Stupor and coma may develop. The patients are often confused and there may be some abnormalities of vision such as hemianopia, blurred vision, and cortical blindness.^[2,6]

In previous reports of PRES, all of these clinical features do not describe in all pediatric PRES patients. In a study of 25 children with PRES, 44% manifested all four clinical signs or symptoms, 32% demonstrated three, 16% had two, and 8% had only one sign or symptom.^[7] Kwon *et al.*^[2] reported 12 patients who presented with seizures (42%), visual disturbances (33%), headache (17%), or altered




Figure 1: (a, b) Axial magnetic resonance image shows abnormal signal intensity, primarily in bilateral parietooccipital and left frontal lobe




Figure 2: Posterior leukoencephalopathy syndrome in a GBS recipient who was taking IVIg (patient 2). Axial magnetic resonance image shows abnormal signal intensity in bilateral basal ganglia and right occipital lobe




Figure 3: (a, b) Axial magnetic resonance image at day 15, showing almost complete resolution of the bilateral parietooccipital and left frontal lobe lesions

Table 1: Clinical and cranial imaging findings

Age	Primary disease	Clinic presentation	Suspected etiology	Lesion on MRI
8	Non-Hodgkin's lymphoma	Seizure (GTC), headache nausea-vomiting, encephalopathy	Cyclophosphamide	Bilateral parieto-oksipital left frontal
3	Guillain-Barré syndrome	Encephalopathy	Intravenous immunoglobuline	Right occipitale, bilateral basal ganglia
7	Acute myeloblastic leukemia	Seizure (GTC), headache nausea-vomiting, visual abnormalities	Cytarabine	Bilateral parieto-oksipital
3	Acute lymphoblastic leukaemia	Headache, nausea-vomiting encephalopathy	Methotrexate	Left occipital
8	Acute lymphoblastic leukaemia	Seizure (focal)	Methotrexate	Bilateral parieto-oksipital
13	Chronic renal failure	Seizure (GTC), headache nausea-vomiting,	Hypertensive crisis	Right occipitale
13	Chronic renal failure	Seizure (focal), headache nausea-vomiting, visual abnormalities	Hypertensive crisis	Diffüz
5	Allogeneic bone marrow transplatation with thalassemi	Seizure (GTC)	Cyclosporine	Bilateral parieto-oksipital
10	Allogeneic bone marrow transplatation with thalassemi	Headache, nausea-vomiting encephalopathy	Cyclosporine	Right occipitale

mental status (8%). In all of our patients, we detected the most common clinical features as seizure (6/9), headache (6/9), and altered consciousness (4/9). The other symptoms were nausea and vomiting and blurred vision.

Many predisposing factors have been proposed including hypertension, immunosuppressive drugs, eclampsia, and renal dysfunction. But, there were some differences in the etiological factors between the children and the adults, as in the clinical features. Hypertension has often been emphasized as a common feature of PRES-associated conditions.^[1] PRES related to hypertension might be due to sudden elevation of blood pressure causing disruption of the autoregulatory mechanisms of the central nervous system vasculature, leading to vasoconstriction and vasodilatation, and breakdown of the blood-brain barrier.^[8,9] Onder *et al.*^[8] detected hypertensive crisis as the most common trigger of PRES in 59%. In our patients, only two of the nine PRES patients had chronic renal failure and hypertensive crisis. The causes of chronic renal failure were focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis. Although

hypertensive encephalopathy is the most common cause of PRES, cases have occurred in the absence of severe hypertension. Renal dysfunction also appears to predispose to PRES, because of chronic uremia or fluid overload. Considering the rare frequency of arteriosclerosis and good plasticity of vessel walls in children, the vulnerability of vessel walls to hypertension was decreased in childhood.^[4]

Posterior leukoencephalopathy syndrome is also obscure during treatment with immunosuppressive and cytotoxic drugs.^[1-4] These drugs may have a direct cytotoxic effect on vascular endothelial cells. Direct toxic effects on the vascular endothelium can produce damage to the blood-brain barrier. The immunosuppressive and cytotoxic drugs may induce and exacerbate hypertension and may lower seizure threshold. Intrathecal chemotherapy may cause cerebral vasospasm, contributing to cerebral vascular autoregulation impairment.^[4,6,10]

Our patients were treated with intrathecal methotrexate, cytarabine, cyclophosphamide, cyclosporine and IVIg

for ALL-L2, AML, nonHodgkin's lymphoma allogeneic bone marrow transplantation, with thalassemia and GBS, respectively. Importantly, seven children were normotensive and were not hypertensive at presentation and follow up. We have detected hypertension only in two patients with chronic renal failure. We were discontinued the immunosuppressive drugs and IVIg treatment in seven of them, and began the antihypertensive management in two hypertensive patients. PRES resolved mostly completely in all of the patients. In hypertensive patients, after the antihypertensive treatment, both patients recovered completely.

In a previously report, characteristic findings of PRES on MRI have been well identified.^[1-3] The MRI findings include oedema involving the white matter in the posterior regions of the cerebral hemispheres, especially bilaterally in the parietooccipital regions. Changes in the gray matter, cerebellum, and brainstem have also been described.^[1,8,11] MRI shows hypotense lesions within the posterior white-matter regions on T1, and hyperintense signal on T2-weighted and FLAIR images. DWI reveals increased diffusion in affected regions, suggesting vasogenic oedema in these areas. The preferential involvement of the parietal and occipital lobes is hypothesized to be related to the less dense sympathetic nervous system innervation of the posterior cerebral circulation.^[12] On MRI studies, DWI and apparent diffusion coefficient (ADC) imaging might be more sensitive for only diagnosis. In our patients, the brain MRI were studied in all of them and revealed typical radiologic changes typical of PRES. Parietal and/or occipital lobe involvement was present in all patients. We also obtained isolated parietal and occipital involvement in six patients.

As a conclusion, the causes of the PRES may be multifactorial. It is important to consider this diagnosis in children presenting with encephalopathy and seizures in an appropriate clinical settings. Because, the clinical

features and neuroimaging findings usually disappear after starting appropriate treatment or discontinuing or dose reducing of the immunosuppressive drugs and with this situation recovery almost completely in the patients with PRES.

References

1. Hinchev J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med* 1996;334:494-500.
2. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. *Pediatr Neurol* 2001;24:361-64.
3. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. *Ann Oncol* 2001;12:1327-9.
4. Koichihara R, Hamano SI, Yamashita S, Tanaka M. Posterior reversible encephalopathy syndrome associated with intravenous immunoglobulin in a patient with Guillain-Barré syndrome. *Pediatr Neurol* 2008;39:123-5.
5. Delanty N, Vaughan C, Frueth S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. *Neurology* 1997;49:686-9.
6. Garg R K. Posterior leukoencephalopathy syndrome. *Postgrad Med J* 2001;77:24-8.
7. Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: Three names for an old syndrome. *J Child Neurol* 1999;14:277-81.
8. Onder AM, Lopez R, Teomete U, Francoeur D, Bhatia R, Knowbi O, et al. Posterior reversible encephalopathy syndrome in the pediatric renal population. *Pediatr Nephrol* 2007;22:1921-9.
9. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: A clinicopathologic study of 20 cases. *Neurology* 1978;28:928-39.
10. Jarosz JM, Howlett DC, Cox TC, Bingham JB. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. *Neuroradiology* 1997;39:711-5.
11. Alehan F, Erol I, Agildere AM, Ozcay F, Baskin E, Cengiz N, et al. Posterior Leukoencephalopathy Syndrome in Children and Adolescents. *J Child Neurol* 2007;22:406-13.
12. Schaefer PW, Buonanno FS, Gonzalez RG, Schwamm LH. Diffusionweighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. *Stroke* 1997;28:1082-5.

Accepted on 02-07-2009

Source of Support: Nil, Conflict of Interest: None declared.